Showing Results for: “Glycemic Index and Diabetes”

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the

Participating, approved products will display the mark on select products to inform consumers The American Diabetes Association (ADA) is pleased to announce the launch of the Better Choices for Life program. The program is designed to aid shoppers in making better choices while shopping and is currently in its pilot stage. Products are selected through a science and evidence-based approach. At this time, prescription drugs are not evaluated or considered for the program. Following an extensive evaluation process, companies applying for participation and passing the evaluation may place the

Analysis of large international DAPA-HF trial participants notes diabetes prevention benefit in patients with heart failure who took 10 mg of medication The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D), according to the study, “Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF,” presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. The original DAPA-HF trial was a phase 3 placebo-controlled international study of

Today, the American Diabetes Association® (ADA) released its 2023 Research Report , highlighting investments in advancing diabetes research and clinical practice. ADA research grants focused on innovative projects with high impact and helped researchers establish collaborative networks to move their innovations into the hands of people living with diabetes. “Research at the ADA is the engine that drives clinical advances by catapulting them into practice. 2023 has brought many prominent achievements. We are incredibly proud of our legacy of highlighting science and eager to build on this

In his State of the Union address tonight President Biden discussed efforts to lower health care costs, make prescription drugs more affordable, and improve access to health care. In response, Lisa Murdock, chief advocacy officer at the American Diabetes Association® (ADA) issued the following statement: “The American Diabetes Association welcomes efforts to reduce health care costs for people living with diabetes. People with diagnosed diabetes now account for one of every four health care dollars spent in the U.S. The ADA has long led the fight to make diabetes treatment more affordable, and

Today, the American Diabetes Association ® (ADA) announced the launch of the Obesity Association . A division of the ADA, the Obesity Association aims to reduce the prevalence of obesity and improve health outcomes. “As part of our mission to prevent diabetes, it is important that we have an even greater focus on addressing one of the key risk factors for type 2 diabetes, obesity. With nearly half of Americans living with diabetes or prediabetes, we must lean into prevention and a holistic approach to health,” said Charles “Chuck” Henderson, the ADA’s chief executive officer. The ADA has been